Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PT005 (Formoterol Fumarate MDI) Dose-Finding Study in COPD
NCT01043601Phase 2Withdrawn
- Sponsor
- Pearl Therapeutics
- Start
- Jul 2010
- Primary completion
- Apr 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of formoterol fumarate MDI in chronic obstructive pulmonary disease (COPD), sponsored by Pearl Therapeutics. Planned start Jul 2010; status: withdrawn.
02
Drugs
formoterol fumarate MDI
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT01043601.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01043601.